Opportunity overview
The Qbtech system QbTest offers an objective method for measuring the three core signs of ADHD - hyperactivity, inattention and impulsivity - in children, adolescents and adults. The test system is used to support diagnosis and to show response to and progress of treatment.
Classification
- CPV85000000 — Health and social work services
Lots
- This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The decision makers where: Brian Cranna - Director of Operations and Transformation North Yorkshire and York Care Group(30/09/25), Jamie Todd - Director of Operations & Transformation DTVF CAMHS, Adult Mental Health and Ridgeway Secure Inpatient Services Care Group (30/09/25), Mel Woodcock - General Manager North Yorkshire, York & Selby CAMHS & LD Services (30/09/25), James Graham - General Manager Durham and Tees Valley Community CAMHS (30/09/25) Steven Smith and Claire Bestford Principle Finance Business Partners NYY and DTV. (30/09/25) Liz Romaniak - Director of Finance, Estate and facilities - (20/10/25) No Conflicts of interest where identified or declared. Qbtech Ltd is the sole provider of QbTest, the only FDA Cleared, EMA registered and CE Marked medical device available in the UK to objectively measure Hyperactivity, Inattention and Impulsivity. QbTest is cleared for use as an aid in the assessment and treatment evaluation of ADHD for those aged 6-60 years old. Details of the FDA Clearances are: To aid in the clinical assessment of ADHD in children (K040894); To aid in the clinical assessment of ADHD in adolescents and adults (K122149); and: To aid in the evaluation of treatment interventions in patients with ADHD (K133382). QbTest is the only ADHD test with NHS cost-efficiency dValue not stated